Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
LIVMARLI (MARALIXIBAT CHLORIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
LIVMARLI
NDA
Get alerts
MARALIXIBAT CHLORIDE | N219485 | MIRUM PHARMACEUTICALS INC
4 strengths
8 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
8 unique patents, 2 exclusivities by expiration date
All strengths
EQ 10MG BASE
EQ 15MG BASE
EQ 20MG BASE
EQ 30MG BASE
Active (8)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
Today
10512657
Oct. 26, 2032
11229647
Feb. 12, 2040
11229661
Oct. 26, 2032
11260053
May. 26, 2031
11376251
Oct. 26, 2032
11497745
Feb. 12, 2040
12296050
Oct. 5, 2043
12350267
Oct. 26, 2032
NCE
Sep. 29, 2026
I-938
Mar. 13, 2027
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 10MG BASE
RLD
8 patents
2 exclusivities
▴
TABLET;ORAL | Approved: Apr 10, 2025
Patents (8)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10512657
Oct 26, 2032
—
—
—
U-4186
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) WHO WEIGH 25 KILOGRAMS AND ABOVE
—
11229647
Feb 12, 2040
—
—
—
U-4187
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE
—
11229661
Oct 26, 2032
—
—
—
U-4186
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) WHO WEIGH 25 KILOGRAMS AND ABOVE
—
11260053
May 26, 2031
—
—
—
U-4187
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE
—
11376251
Oct 26, 2032
—
—
—
U-4187
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE
—
11497745
Feb 12, 2040
—
—
—
U-4187
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE
—
12296050
Oct 5, 2043
—
—
Yes
U-4186
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) WHO WEIGH 25 KILOGRAMS AND ABOVE
—
12350267
Oct 26, 2032
—
—
—
U-3973
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
—
Exclusivities (2)
Code
Date
Status
I-938
Mar 13, 2027
< 1 year
NCE
Sep 29, 2026
< 1 year
#002 — EQ 15MG BASE
RLD
8 patents
2 exclusivities
▾
TABLET;ORAL | Approved: Apr 10, 2025
#003 — EQ 20MG BASE
RLD
8 patents
2 exclusivities
▾
TABLET;ORAL | Approved: Apr 10, 2025
#004 — EQ 30MG BASE
RLD
8 patents
2 exclusivities
▾
TABLET;ORAL | Approved: Apr 10, 2025